Castle Biosciences (NASDAQ:CSTL) Insider Derek Maetzold Sells 2,763 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 2,763 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $20.20, for a total transaction of $55,812.60. Following the completion of the transaction, the insider owned 1,946 shares in the company, valued at $39,309.20. This trade represents a 58.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Trading Down 1.9%

Shares of NASDAQ CSTL traded down $0.39 during midday trading on Friday, reaching $20.15. The stock had a trading volume of 289,270 shares, compared to its average volume of 406,556. The firm has a market cap of $611.15 million, a price-to-earnings ratio of -45.80 and a beta of 1.11. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $44.28. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.53 and a current ratio of 6.75. The company’s 50 day moving average price is $23.57 and its 200 day moving average price is $31.81.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.49). The firm had revenue of $84.23 million for the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. As a group, sell-side analysts expect that Castle Biosciences, Inc. will post -1.4 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CSTL. Amundi lifted its position in shares of Castle Biosciences by 15,811.5% during the 1st quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after acquiring an additional 4,111 shares during the period. AQR Capital Management LLC raised its holdings in Castle Biosciences by 548.9% during the first quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after buying an additional 115,907 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Castle Biosciences by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after buying an additional 655 shares during the last quarter. Jones Financial Companies Lllp raised its holdings in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after buying an additional 2,648 shares during the last quarter. Finally, Legal & General Group Plc raised its holdings in Castle Biosciences by 34.7% during the second quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock worth $713,000 after buying an additional 8,992 shares during the last quarter. Institutional investors and hedge funds own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Canaccord Genuity Group dropped their price target on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research report on Monday, April 20th. Guggenheim boosted their target price on shares of Castle Biosciences from $43.00 to $47.00 and gave the company a “buy” rating in a research report on Monday, January 26th. Morgan Stanley upgraded shares of Castle Biosciences to a “buy” rating in a research report on Monday, March 2nd. Wall Street Zen downgraded shares of Castle Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Zacks Research upgraded shares of Castle Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $45.33.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.